Published in Pharmacol Ther on July 01, 2003
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Statins may aggravate myasthenia gravis. Muscle Nerve (2008) 1.66
The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol (2005) 1.18
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med (2007) 1.13
Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol (2013) 1.00
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. Br J Pharmacol (2009) 0.94
Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation. J Neurochem (2009) 0.92
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes. J Diabetes Investig (2013) 0.85
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol (2006) 0.84
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther (2012) 0.84
Effect of surgical treatment on lipid peroxidation parameters and antioxidant status in the serum of patients with peripheral arterial disease. Dis Markers (2013) 0.83
Simvastatin protects auditory hair cells from gentamicin-induced toxicity and activates Akt signaling in vitro. BMC Neurosci (2011) 0.82
Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J Immunol (2009) 0.81
Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res (2009) 0.80
A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension. Pulm Circ (2016) 0.79
Chemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci (2012) 0.79
Unsupervised analysis of classical biomedical markers: robustness and medical relevance of patient clustering using bioinformatics tools. PLoS One (2012) 0.79
Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4/NF-kB signaling pathway. Inflammopharmacology (2016) 0.78
Heme Oxygenase-1 Expression Affects Murine Abdominal Aortic Aneurysm Progression. PLoS One (2016) 0.78
eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol (2008) 0.77
Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. ScientificWorldJournal (2012) 0.77
Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart (2014) 0.76
New frontiers in the treatment of diabetic dyslipidemia. Rev Diabet Stud (2013) 0.76
Protective Effects of Simvastatin, a Lipid Lowering Agent, against Oxidative Damage in Experimental Diabetic Rats. J Lipids (2011) 0.76
SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci (2015) 0.75
Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. Korean J Anesthesiol (2010) 0.75
Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B. Exp Ther Med (2016) 0.75
Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels (2017) 0.75
Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. J Thorac Dis (2017) 0.75
Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf (2017) 0.75
CD36 and macrophages in atherosclerosis. Cardiovasc Res (2007) 1.85
Poor prescribing is continual. BMJ (2006) 1.55
Cardiac effects of amiloride and of enalapril in the spontaneously hypertensive rat. J Hypertens (2003) 1.41
Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One (2011) 1.24
Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol (2008) 1.18
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet (2012) 1.12
Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J (2003) 1.12
Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction. Circulation (2009) 1.08
Platelet-derived nitric oxide signaling and regulation. Circ Res (2007) 1.06
Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci (Landmark Ed) (2011) 1.02
A genetic variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis (2005) 1.02
Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens (2009) 0.94
Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One (2012) 0.93
Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens (2010) 0.92
A genetic variant of apolipoprotein M increases susceptibility to coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol (2007) 0.92
The genetics of aspirin resistance. Int J Clin Pract (2007) 0.90
Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J (2009) 0.90
Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. J Am Heart Assoc (2013) 0.89
Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol (2009) 0.89
beta-Actin regulates platelet nitric oxide synthase 3 activity through interaction with heat shock protein 90. Proc Natl Acad Sci U S A (2007) 0.88
17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. Clin Exp Pharmacol Physiol (2007) 0.88
Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS One (2013) 0.88
Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells. J Physiol (2006) 0.88
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 0.88
Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res (2009) 0.87
Pyridoxine inhibits endothelial NOS uncoupling induced by oxidized low-density lipoprotein via the PKCα signalling pathway in human umbilical vein endothelial cells. Br J Pharmacol (2012) 0.87
Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. J Mol Cell Cardiol (2012) 0.87
Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. Br J Clin Pharmacol (2011) 0.86
beta-adrenoceptors and potassium channels. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.86
Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond) (2005) 0.85
Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res (2003) 0.85
l-Tetrahydropalmatine, an active component of Corydalis yanhusuo W.T. Wang, protects against myocardial ischaemia-reperfusion injury in rats. PLoS One (2012) 0.85
Protection of angiotensin II-induced vascular hypertrophy in vascular smooth muscle-targeted receptor activity-modifying protein 2 transgenic mice. Hypertension (2009) 0.84
Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress. PLoS One (2013) 0.84
The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovasc Dis (2012) 0.83
Sca-1+ cardiac progenitor cell therapy with cells overexpressing integrin-linked kinase improves cardiac function after myocardial infarction. Transplantation (2013) 0.83
Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats. PLoS One (2012) 0.83
Effects of beta-adrenoceptor stimulation on endothelial nitric-oxide synthase phosphorylation of human umbilical vein endothelial cells. Acta Pharmacol Sin (2003) 0.83
Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats. J Am Heart Assoc (2014) 0.83
Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates. Cardiovasc Res (2007) 0.82
Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol (2002) 0.82
Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci (2002) 0.82
S-nitrosophytochelatins: investigation of the bioactivity of an oligopeptide nitric oxide delivery system. Biomacromolecules (2011) 0.81
Endothelial function and arterial compliance are not impaired in subjects with heart failure of non-ischemic origin. J Card Fail (2009) 0.81
Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. Int J Vitam Nutr Res (2010) 0.81
Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol (2014) 0.81
Pyridoxine prevents dysfunction of endothelial cell nitric oxide production in response to low-density lipoprotein. Atherosclerosis (2005) 0.80
Renal dopamine receptors and hypertension. J Hypertens (2003) 0.80
Metastatic paraganglioma: management of orthostatic hypotension - a case report. JRSM Cardiovasc Dis (2012) 0.79
Activation of endothelial nitric oxide synthase is dependent on its interaction with globular actin in human umbilical vein endothelial cells. J Mol Cell Cardiol (2011) 0.79
The physician's role in prescribing physical activity for the prevention and treatment of essential hypertension. JRSM Cardiovasc Dis (2012) 0.78
Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteine. Atherosclerosis (2007) 0.78
Rabbit aortic endothelial dysfunction by low-density lipoprotein is attenuated by L-arginine, L-ascorbate and pyridoxine. Br J Pharmacol (2003) 0.78
Platelet-derived microparticles are implicated in remote ischemia conditioning in a rat model of cerebral infarction. CNS Neurosci Ther (2013) 0.77
Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets. J Mol Cell Cardiol (2008) 0.77
Nutraceuticals: is there good science behind the hype? Br J Clin Pharmacol (2013) 0.77
Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor. FASEB J (2003) 0.76
Platelet nitric oxide signalling in heart failure: role of oxidative stress. Cardiovasc Res (2011) 0.76
Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens (2013) 0.76
Drugs for addiction: a therapeutic area in need of a 'shot in the arm'. Br J Clin Pharmacol (2014) 0.75
From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box. Br J Clin Pharmacol (2015) 0.75
Catheter-based renal denervation for treatment of resistant hypertension. JRSM Cardiovasc Dis (2013) 0.75
Editors' pick 2012. Br J Clin Pharmacol (2013) 0.75
Pyridoxine increases nitric oxide biosynthesis in human platelets. Int J Vitam Nutr Res (2009) 0.75
Editors' pick 2014. Br J Clin Pharmacol (2015) 0.75
Statins and vascular protection: a 'radical' view. J Hypertens (2002) 0.75
Cardiac stem cell therapy: present and future. Br J Clin Pharmacol (2006) 0.75
Biological therapies: a long way on from Jenner. Br J Clin Pharmacol (2013) 0.75
Differential effects of beta-adrenoreceptor antagonists on central and peripheral blood pressure at rest and during exercise. Br J Clin Pharmacol (2010) 0.75
Editors' pick 2010. Br J Clin Pharmacol (2011) 0.75
Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ (2011) 0.75
Editors' report, November 2010. Br J Clin Pharmacol (2011) 0.75
Inhibition of endothelial nitric oxide generation by low-density lipoprotein is partially prevented by L-arginine and L-ascorbate. Atherosclerosis (2004) 0.75
In Memoriam: Dr Graham Jackson, 1947-2016. Int J Clin Pract (2016) 0.75
Editors' report, November 2013. Br J Clin Pharmacol (2014) 0.75